Effectiveness of Wellbeing Intervention for Chronic Kidney Disease (WICKD): results of a randomised controlled trial.
E-mental health
Indigenous
Kidney disease
Renal
Wellbeing
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
19 04 2021
19 04 2021
Historique:
received:
13
11
2020
accepted:
05
04
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
1
3
2022
Statut:
epublish
Résumé
End stage kidney disease (ESKD) is associated with many losses, subsequently impacting mental wellbeing. Few studies have investigated the efficacy of psychosocial interventions for people with ESKD and none exist for Indigenous people, a population in which the ESKD burden is especially high. This three-arm, waitlist, single-blind randomised controlled trial examined efficacy of the Stay Strong App in improving psychological distress (Kessler distress scale; K10), depressive symptoms (adapted Patient Health Questionnaire; PHQ-9), quality of life (EuroQoL; EQ. 5D) and dialysis adherence among Indigenous Australians undergoing haemodialysis in central and northern Australia (Alice Springs and Darwin), with follow up over two 3-month periods. Effects of immediate AIMhi Stay Strong App treatment were compared with those from a contact control app (The Hep B Story) and treatment as usual (TAU). Control conditions received the Stay Strong intervention after 3 months. Primary analyses of the full sample (N = 156) showed statistically significant decreases in K10 and PHQ-9 scores at 3 months for the Hep B Story but not for the Stay Strong app or TAU. Restricting the sample to those with moderate to severe symptoms of distress or depression (K10 > =25 or PHQ-9 > =10) showed significant decreases in K10 and PHQ-9 scores for both Stay Strong and Hep B Story. No significant differences were observed for the EQ-5D or dialysis attendance. Findings suggest that talking to people about their wellbeing and providing information relevant to kidney health using culturally adapted, locally relevant apps improve the wellbeing of people on dialysis. Further research is required to replicate these findings and identify active intervention components. ACTRN12617000249358 ; 17/02/2017.
Sections du résumé
BACKGROUND
End stage kidney disease (ESKD) is associated with many losses, subsequently impacting mental wellbeing. Few studies have investigated the efficacy of psychosocial interventions for people with ESKD and none exist for Indigenous people, a population in which the ESKD burden is especially high.
METHODS
This three-arm, waitlist, single-blind randomised controlled trial examined efficacy of the Stay Strong App in improving psychological distress (Kessler distress scale; K10), depressive symptoms (adapted Patient Health Questionnaire; PHQ-9), quality of life (EuroQoL; EQ. 5D) and dialysis adherence among Indigenous Australians undergoing haemodialysis in central and northern Australia (Alice Springs and Darwin), with follow up over two 3-month periods. Effects of immediate AIMhi Stay Strong App treatment were compared with those from a contact control app (The Hep B Story) and treatment as usual (TAU). Control conditions received the Stay Strong intervention after 3 months.
RESULTS
Primary analyses of the full sample (N = 156) showed statistically significant decreases in K10 and PHQ-9 scores at 3 months for the Hep B Story but not for the Stay Strong app or TAU. Restricting the sample to those with moderate to severe symptoms of distress or depression (K10 > =25 or PHQ-9 > =10) showed significant decreases in K10 and PHQ-9 scores for both Stay Strong and Hep B Story. No significant differences were observed for the EQ-5D or dialysis attendance.
CONCLUSIONS
Findings suggest that talking to people about their wellbeing and providing information relevant to kidney health using culturally adapted, locally relevant apps improve the wellbeing of people on dialysis. Further research is required to replicate these findings and identify active intervention components.
TRIAL REGISTRATION
ACTRN12617000249358 ; 17/02/2017.
Identifiants
pubmed: 33866968
doi: 10.1186/s12882-021-02344-8
pii: 10.1186/s12882-021-02344-8
pmc: PMC8054368
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Références
Health Promot J Austr. 2007 Dec;18(3):208-16
pubmed: 18201163
JMIR Mhealth Uhealth. 2019 Oct 7;7(10):e14877
pubmed: 31593537
World Psychiatry. 2017 Oct;16(3):287-298
pubmed: 28941113
Aust N Z J Public Health. 2001 Dec;25(6):494-7
pubmed: 11824981
BMC Psychol. 2019 Jan 8;7(1):2
pubmed: 30621791
Soc Sci Med. 2019 Jul;233:138-157
pubmed: 31200269
Aust Fam Physician. 2008 Dec;37(12):996-1000
pubmed: 19142272
Semin Dial. 2005 Mar-Apr;18(2):98-102
pubmed: 15771652
Semin Dial. 2005 Mar-Apr;18(2):142-6
pubmed: 15771659
BMJ. 2000 Sep 16;321(7262):694-6
pubmed: 10987780
Aust J Rural Health. 2009 Aug;17(4):174-82
pubmed: 19664081
Qual Life Res. 2016 Sep;25(9):2161-78
pubmed: 27165149
Kidney Int Rep. 2016 Sep 20;2(1):94-107
pubmed: 29318209
BMC Psychiatry. 2013 Oct 20;13:271
pubmed: 24139186
Psychol Assess. 2010 Jun;22(2):203-12
pubmed: 20528048
BMC Nephrol. 2020 Apr 15;21(1):130
pubmed: 32293331
Kidney Int. 2012 Feb;81(3):247-55
pubmed: 22012131
Clin Psychol Rev. 2016 Apr;45:102-14
pubmed: 27111302
J Med Internet Res. 2017 Jul 20;19(7):e256
pubmed: 28729237
Clin J Am Soc Nephrol. 2006 May;1(3):349-52
pubmed: 17699229
J Med Internet Res. 2016 Dec 20;18(12):e330
pubmed: 27998876
Kidney Int. 2013 Jul;84(1):179-91
pubmed: 23486521
J Affect Disord. 2017 Aug 15;218:15-22
pubmed: 28456072
BMC Nephrol. 2015 Oct 22;16:168
pubmed: 26494472